Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).

Sakaguchi H, Umeda K, Kato I, Sakaguchi K, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito A, Noma H, Horibe K, Taga T, Adachi S, Transplantation and Cellular Therapy Committee of Japanese Childhood Cancer Group.

Open source

DOI: 10.1136/bmjopen-2022-070051
Published: 2023-04-17
Container: BMJ Open
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2022-070051,
  title = {Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).},
  author = {Sakaguchi H and  Umeda K and  Kato I and  Sakaguchi K and  Hiramatsu H and  Ishida H and  Yabe H and  Goto H and  Kawahara Y and  Yamashita YI and  Sanada M and  Deguchi T and  Takahashi Y and  Saito A and  Noma H and  Horibe K and  Taga T and  Adachi S and  Transplantation and Cellular Therapy Committee of Japanese Childhood Cancer Group.},
  year = {2023},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2022-070051},
  url = {https://doi.org/10.1136/bmjopen-2022-070051}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).
AU  - Sakaguchi H
AU  -  Umeda K
AU  -  Kato I
AU  -  Sakaguchi K
AU  -  Hiramatsu H
AU  -  Ishida H
AU  -  Yabe H
AU  -  Goto H
AU  -  Kawahara Y
AU  -  Yamashita YI
AU  -  Sanada M
AU  -  Deguchi T
AU  -  Takahashi Y
AU  -  Saito A
AU  -  Noma H
AU  -  Horibe K
AU  -  Taga T
AU  -  Adachi S
AU  -  Transplantation and Cellular Therapy Committee of Japanese Childhood Cancer Group.
PY  - 2023
JO  - BMJ Open
DO  - 10.1136/bmjopen-2022-070051
UR  - https://doi.org/10.1136/bmjopen-2022-070051
ER  -

APA

H, S., K, U., I, K., K, S., H, H., H, I., H, Y., H, G., Y, K., YI, Y., M, S., T, D., Y, T., A, S., H, N., K, H., T, T., S, A., & Group., T. A. C. T. C. O. J. C. C. (2023). Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).. BMJ Open. https://doi.org/10.1136/bmjopen-2022-070051

Source records

europe-pmc · retrieved 2026-09-26T05:26:09.489Z
doaj · retrieved 2026-09-26T05:26:09.476Z